4-oxo-4,5,6,7-tetrahydro-3-isopropylindazole | 155590-17-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-oxo-4,5,6,7-tetrahydro-3-isopropylindazole
• 英文别名: 3-Propan-2-yl-1,5,6,7-tetrahydroindazol-4-one
• CAS: 155590-17-3
• 化学式: C₁₀H₁₄N₂O
• 分子量: 178.234
• InChiKey: SGIHEGKTYPFTFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-oxo-4,5,6,7-tetrahydro-3-isopropylindazole 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 6.0h， 以95%的产率得到4-hydroxy-4,5,6,7-tetrahydro-3-isopropylindazole
  参考文献：
  名称：

  Kim, Jin Il; Kim, Byung Chul; Moon, Seung Wook, Heterocycles, 1995, vol. 41, # 7, p. 1471 - 1478

  摘要：

  DOI：
• 作为产物：
  描述：

  2-isobutyrylcyclohexane-1,3-dione 在 肼 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以94%的产率得到4-oxo-4,5,6,7-tetrahydro-3-isopropylindazole
  参考文献：
  名称：

  Kim, Jin Il; Kim, Byung Chul; Moon, Seung Wook, Heterocycles, 1995, vol. 41, # 7, p. 1471 - 1478

  摘要：

  DOI：

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US11168088B2

  公开（公告）日：2021-11-09

  The present disclosure relates to pyridinamine-substituted heterotricyclo compounds, a preparation method thereof, and a use thereof in medicines. Specifically, a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, a preparation method and a use thereof are disclosed, wherein the groups in the formula (I) are as defined in the Description and claims.

  本公开涉及吡啶胺取代的杂环化合物、其制备方法及其在药物中的用途。具体地说，本发明公开了一种式（I）化合物或其药学上可接受的盐、立体异构体、溶液剂或原药，以及其制备方法和用途，其中式（I）中的基团如说明书和权利要求书中所定义。
• PYRIDYLAMINO SUBSTITUTED HETEROTRICYCLIC COMPOUNDS, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US20200039983A1

  公开（公告）日：2020-02-06

  The present disclosure relates to pyridinamine-substituted heterotricyclo compounds, a preparation method thereof, and a use thereof in medicines. Specifically, a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, a preparation method and a use thereof are disclosed, wherein the groups in the formula (I) are as defined in the Description and claims.
• US9931407B2
  申请人：——

  公开号：US9931407B2

  公开（公告）日：2018-04-03
• [EN] SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME<br/>[FR] CONJUGUÉS DE MÉDICAMENT À BASE DE SILICIUM ET LEURS PROCÉDÉS D'UTILISATION
  申请人：BLINKBIO INC

  公开号：WO2016183359A1

  公开（公告）日：2016-11-17

  Described herein are silicon based conjugates capable of delivering one or more pay load moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more pay load moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.